The strong Q3 beat and reiterated guidance signal accelerating commercial execution from both Korlym and Lifyorli. The key near-term catalyst is the December 17 PDUFA date for relacorilant in Cushing's syndrome, which could open a large new market. Monitor EU approval decision expected by year-end and BELLA Part B/C data in 2027.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Corcept Therapeutics reported Q3 2026 revenue of $340.5M (+64% YoY) and diluted EPS of $1.01, well above consensus of $0.84. Lifyorli revenue grew 92% QoQ to $91.4M, and the company reiterated its 2026 revenue guidance of $1.1B-$1.2B. The PDUFA date for relacorilant in Cushing's syndrome is December 17, 2026.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $340.5M, up 64% from $207.6M in Q3 2025
- Diluted EPS $1.01 vs $0.16 in Q3 2025, beating consensus of $0.84
- Lifyorli revenue $91.4M, up 92% from $47.6M in Q2 2026
- Korlym and authorized generic revenue $249.1M, up 19% from Q2 2026
- Net income $126.8M vs $19.7M in Q3 2025
- Cash and investments $662.3M, up $117.7M from Q2 2026
- 2026 revenue guidance reiterated at $1.1B-$1.2B
- PDUFA date for relacorilant NDA in Cushing's syndrome: December 17, 2026
- CHMP recommended EU approval for relacorilant in platinum-resistant ovarian cancer
- BELLA Part A trial showed median PFS 7.2 months, ORR 59%, 6-month OS 88%
Financial Impact
Revenue $340.5M (+64% YoY), diluted EPS $1.01, net income $126.8M
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Korlym and authorized generic | $249.1M | +19.0% |
| Lifyorli | $91.4M | +92.0% |
Risk Factors
- Relacorilant NDA in Cushing's syndrome faces FDA decision on December 17, 2026; outcome uncertain
- Lifyorli launch trajectory may slow as initial pent-up demand normalizes
- R&D spending remains elevated as pipeline expands into multiple Phase 2/3 trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-069494 |
| Document: cort-20261103.htm | 0001628280-26-069494 |
| Document: 0001628280-26-069494-index-headers.html | 0001628280-26-069494 |
| Document: 0001628280-26-069494-index.html | 0001628280-26-069494 |
| Document: 0001628280-26-069494.txt | 0001628280-26-069494 |
| 8-K Data (Synthetic) | 0001628280-26-069494 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 4, 2026 today | Insider Cluster | No price | awaiting T+20 | awaiting T+20 | No price |
Nov 3, 2026 1d ago | 8-K | $77.90 | awaiting T+20 | awaiting T+20 | $79.22 (+1.69%) |
Nov 2, 2026 2d ago | Institutional Cluster | $81.93 | awaiting T+20 | awaiting T+20 | $79.22 (+3.31%) |
Oct 27, 2026 8d ago | SC 13G/A | $86.28 | awaiting T+20 | awaiting T+20 | $79.22 (−8.18%) |
Oct 5, 2026 4w ago | Insider Cluster | $119.57 $81.93 | ▼ −31.48% | ▼ −28.30% | $79.22 (−33.75%) |
Sep 23, 2026 6w ago | 8-K | $112.94 $116.28 | ▲ +2.96% | ▲ +2.27% | $79.22 (−29.86%) |
Sep 16, 2026 7w ago | Insider Cluster | $114.86 $113.37 | ▲ +1.30% | ▲ +2.50% | $79.22 (+31.03%) |
Sep 16, 2026 7w ago | Insider Cluster | $114.86 $113.37 | ▲ +1.30% | ▲ +2.75% | $79.22 (+31.03%) |
Aug 28, 2026 9w ago | Insider Cluster | $113.35 $114.74 | ▲ +1.23% | ▲ +1.60% | $79.22 (−30.11%) |
Aug 28, 2026 9w ago | Insider Cluster | $113.35 $114.74 | ▲ +1.23% | ▲ +1.60% | $79.22 (−30.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers